Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
44 studies found for:    Inclusion Body Myositis
Show Display Options
Rank Status Study
1 Completed Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Biological: BYM338;   Biological: Placebo
2 Completed Arimoclomol in Sporadic Inclusion Body Myositis
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
3 Not yet recruiting Study of Arimoclomol in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
4 Completed Blood-flow Restricted Exercise in Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Other: Blood-flow restricted training;   Drug: Care as usual
5 Active, not recruiting An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Condition: Sporadic Inclusion Body Myositis
Interventions: Drug: Bimagrumab;   Drug: Placebo
6 Completed Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis (sIBM)
Intervention: Drug: BYM338 (Bimagrumab)
7 Recruiting Natalizumab in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis (IBM)
Intervention: Drug: Natalizumab
8 Completed Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention: Drug: Etanercept
9 Completed Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention:
10 Active, not recruiting Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Conditions: Becker Muscular Dystrophy;   Sporadic Inclusion Body Myositis
Intervention: Biological: rAAV1.CMV.huFollistatin344
11 Completed Lithium in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Intervention:
12 Completed Immune Abnormalities in Sporadic Inclusion Body Myositis
Conditions: Sporadic;   Inclusion Body;   Myositis
Intervention:
13 Completed Alemtuzumab to Treat Sporadic Inclusion Body Myositis
Condition: Myositis, Inclusion Body
Intervention: Drug: Alemtuzumab (Campath)
14 Recruiting Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Condition: Inclusion Body Myositis (IBM)
Interventions: Drug: Rapamycin;   Drug: Placebo
15 Completed Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Condition: Sporadic Inclusion Body Myositis
Interventions: Drug: BYM338/bimagrumab;   Drug: Placebo
16 Completed Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
Conditions: Dermatomyositis;   Inclusion Body Myositis;   Polymyositis
Intervention: Drug: Gamma Globulin
17 Unknown  A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Condition: Idiopathic Inflammatory Myopathy
Intervention:
18 Completed Epidemiological Study of Inflammatory Myopathies in a French Region
Condition: Polymyositis
Intervention:
19 Not yet recruiting MYOPROSP - a Prospective Cohort Study in Myositis
Conditions: Myositis;   Idiopathic Inflammatory Myopathy
Intervention:
20 Completed Anakinra in Myositis
Conditions: Polymyositis;   Dermatomyositis;   Inclusion Body Myositis
Intervention: Drug: Anakinra

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.